Serum HE4 level as a biomarker to predict the recurrence of gynecologic cancers

Current Drug Targets

Volumn 18, Issue 10, 2017, Pages 1158-1164

  Li, Jinping ^a,b   Chen, Haibin ^c   Curcuru, John R ^b   Patel, Sheena ^b   Johns, Taylor O ^b   Patel, Dimple ^b   Qian, Hua ^d   Jiang, Shi Wen ^a,b  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^d Taizhou People's Hospital   (China)

Author keywords

Cancer recurrence; Endometrial cancers; Gynecologic cancers; HE4; Ovarian cancers; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CARBOPLATIN; HUMAN EPIDIDYMIS PROTEIN 4; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

CANCER CELL; CANCER PROGNOSIS; CANCER RECURRENCE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; HUMAN EPIDIDYMIS PROTEIN 4 BLOOD LEVEL; LUNG ADENOCARCINOMA; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW; SCIENTIFIC LITERATURE; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; TREATMENT RESPONSE; ANIMAL; BLOOD; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE; ENDOMETRIUM TUMOR; METABOLISM; OVARY TUMOR; PROGNOSIS; TUMOR RECURRENCE;

ANIMALS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS;

EID: 85025176330     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450118666170404154929     Document Type: Review

References (58)

1. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002; 20(5): 1161-3.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80(6): 827-41.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
4. Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002; 3(9): 529-36.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917.
6. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991; 45(2): 350-7.
7. Sandhu N, Karlsen MA, Hogdall C, Laursen IA, Christensen IJ, Hogdall EV. Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer. Scand J Clin Lab Invest 2014; 74(6): 477-84.
8. Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med 2012; 50(8): 1439-46.
9. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Jr., Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012; 206(4): 349.e1-7.
10. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100(8): 1315-9.
11. Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011; 205(4): 358.e1-6.
12. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem 2011; 44(10-11): 884-8.
13. Hallamaa M, Huhtinen K, Suvitie P, Perheentupa A. Serum concentrations of HE4 change little during in vitro fertilization. Acta Obstet Gynecol Scand 2014; 93(7): 640-6.
14. McLemore MR, Aouizerat BE, Lee KA, et al. A comparison of the cyclic variation in serum levels of CA125 across the menstrual cycle using two commercial assays. Biol Res Nurs 2012; 14(3): 250-6.
15. Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol 2013; 8: 11.
16. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203(3): 228.e1-6.
17. Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol 2012; 124(2): 270-5.
18. Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009; 9(6): 555-66.
19. Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol 2012; 33(6): 2117-23.
20. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010; 31(2): 113-9.
21. Li J, Chen H, Mariani A, et al. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci 2013; 14(3): 6026-43.
22. Brennan DJ, Hackethal A, Mann KP, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer 2015; 15: 33.
23. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002; 3(7): 509-19.
24. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003; 4(7): 544-58.
25. Schalkwijk J, Wiedow O, Hirose S. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J 1999; 340 (Pt 3): 569-77.
26. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994; 11(6): 733-41.
27. Bingle L, Cross SS, High AS, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006; 7: 61.
28. Moreau T, Baranger K, Dade S, Dallet-Choisy S, Guyot N, Zani ML. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90(2): 284-95.
29. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006; 110(1): 21-35.
30. Hurle B, Swanson W, Green ED. Comparative sequence analyses reveal rapid and divergent evolutionary changes of the WFDC locus in the primate lineage. Genome Res 2007; 17(3): 276-86.
31. Chhikara N, Saraswat M, Tomar AK, Dey S, Singh S, Yadav S. Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor. PLoS One 2012; 7(11): e47672.
32. Rakashanda S, Rana F, Rafiq S, Masood A, Amin S. Role of proteases in cancer: A review. 2012.
33. Wang H, Zhu L, Gao J, Hu Z, Lin B. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells. Oncol Rep 2015; 33(1): 403-12.
34. Lu Q, Chen H, Senkowski C, et al. Recombinant HE4 protein promotes proliferation of pancreatic and endometrial cancer cell lines. Oncol Rep 2016; 35(1): 163-70.
35. Ribeiro JR, Schorl C, Yano N, et al. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. J Ovarian Res 2016; 9: 18.
36. Lee S, Choi S, Lee Y, Chung D, Hong S, Park N. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer. J Obstet Gynaecol Res 2017; 43(1): 220-7.
37. Pecorelli SC, Petterson WT, Denedet F, Shepard JL, Figo JH. Annual report on the results of treatment in gynecological cancer. J Epidemiol Biostat 1988; 75-102.
38. Schink JC. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 1999; 26(1 Suppl 1): 2-7.
39. Vallius T, Hynninen J, Auranen A, et al. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol 2014; 35(12): 12389-95.
40. Manganaro L, Michienzi S, Vinci V, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep 2013; 30(5): 2481-7.
41. Nassir M, Guan J, Luketina H, et al. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. Tumour Biol 2016; 37(3): 3009-16.
42. Steffensen KD, Waldstrom M, Brandslund I, et al. Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. Oncol Lett 2016; 11(6): 3967-74.
43. Braicu EI, Luketina H, Richter R, et al. HIF1alpha is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer-a study of the OVCAD Consortium. Onco Targets Ther 2014; 7: 1563-9.
44. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373(9658): 125-36.
45. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100(23): 1707-16.
46. Smith CJ, Heeren M, Nicklin JL, et al. Efficacy of routine followup in patients with recurrent uterine cancer. Gynecol Oncol 2007; 107(1): 124-9.
47. Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006; 101(3): 520-9.
48. Galgano MT, Hampton GM, Frierson HF, Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19(6): 847-53.
49. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65(6): 2162-9.
50. Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients wiThendometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008; 110(2): 196-201.
51. Jiang SW, Chen H, Dowdy S, et al. HE4 transcription-and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci 2013; 14(11): 22655-77.
52. Angioli R, Capriglione S, Scaletta G, et al. The role of HE4 in endometrial cancer recurrence: how to choose the optimal followup program. Tumour Biol 2016; 37(4): 4973-8.
53. Kamei M, Yamashita S, Tokuishi K, et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res 2010; 30(11): 4779-83.
54. Huang TH, Jiang SW, Qin LY, et al. Expression and Diagnostic Value of HE4 in Pancreatic Adenocarcinoma. Int J Mol Sci 2015; 16(2): 2956-70.
55. Guo YD, Wang JH, Lu H, et al. The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer. Tumour Biol 2015; 36(4): 2457-64.
56. Lamy PJ, Plassot C, Pujol JL. Serum HE4: An independent prognostic factor in non-small cell lung cancer. PLoS One 2015; 10(6): e0128836.
57. Jiang Y, Wang C, Lv B, Ma G, Wang L. Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer. Int J Clin Exp Med 2014; 7(12): 5568-72.
58. Yamashita S, Tokuishi K, Moroga T, et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumour Biol 2012; 33(6): 2365-70.